Reported Earnings • May 15
First quarter 2026 earnings released: EPS: NT$0.67 (vs NT$0.15 loss in 1Q 2025) First quarter 2026 results: EPS: NT$0.67 (up from NT$0.15 loss in 1Q 2025). Revenue: NT$93.0m (down 3.0% from 1Q 2025). Net income: NT$14.5m (up NT$17.7m from 1Q 2025). Profit margin: 16% (up from net loss in 1Q 2025). The move to profitability was driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 69 percentage points per year, which is a significant difference in performance. Reported Earnings • Mar 13
Full year 2025 earnings released: NT$0.43 loss per share (vs NT$0.86 profit in FY 2024) Full year 2025 results: NT$0.43 loss per share (down from NT$0.86 profit in FY 2024). Revenue: NT$385.7m (down 15% from FY 2024). Net loss: NT$9.36m (down 151% from profit in FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 78 percentage points per year, which is a significant difference in performance. Announcement • Mar 12
Sofiva Genomics Co.,Ltd., Annual General Meeting, Jun 03, 2026 Sofiva Genomics Co.,Ltd., Annual General Meeting, Jun 03, 2026. Location: 3 floor no,195, hsing chung rd., neihu district, taipei city Taiwan Board Change • Feb 25
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Yi Shan Pan was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 15
Third quarter 2025 earnings released: NT$0.05 loss per share (vs NT$0.081 profit in 3Q 2024) Third quarter 2025 results: NT$0.05 loss per share (down from NT$0.081 profit in 3Q 2024). Revenue: NT$93.4m (down 12% from 3Q 2024). Net loss: NT$1.17m (down 167% from profit in 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 62 percentage points per year, which is a significant difference in performance. Reported Earnings • Aug 15
Second quarter 2025 earnings released: NT$0.02 loss per share (vs NT$0.45 profit in 2Q 2024) Second quarter 2025 results: NT$0.02 loss per share (down from NT$0.45 profit in 2Q 2024). Revenue: NT$100.7m (down 18% from 2Q 2024). Net loss: NT$410.0k (down 104% from profit in 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 57% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings. New Risk • Jul 25
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 22% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.3% average weekly change). Profit margins are more than 30% lower than last year (0.6% net profit margin). Market cap is less than US$100m (NT$702.9m market cap, or US$23.8m). Buy Or Sell Opportunity • Jul 22
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 16% to NT$30.00. The fair value is estimated to be NT$38.05, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 4.5% over the last 3 years. Earnings per share has declined by 50%. Upcoming Dividend • Jun 22
Upcoming dividend of NT$0.30 per share Eligible shareholders must have bought the stock before 27 June 2025. Payment date: 21 July 2025. The company is paying out more than 100% of its profits and is paying out 81% of its cash flow. Trailing yield: 0.9%. Lower than top quartile of Taiwanese dividend payers (5.3%). Lower than average of industry peers (3.7%). Declared Dividend • Jun 07
Dividend increased to NT$0.30 Dividend of NT$0.30 is 51% higher than last year. Ex-date: 27th June 2025 Payment date: 21st July 2025 Dividend yield will be 0.9%, which is lower than the industry average of 3.1%. Payout Ratios Payout ratio: 240%. Cash payout ratio: 81%. New Risk • May 15
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 0.6% Last year net profit margin: 4.2% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 22% per year over the past 5 years. Minor Risks Profit margins are more than 30% lower than last year (0.6% net profit margin). Market cap is less than US$100m (NT$729.9m market cap, or US$24.2m). Announcement • May 07
Sofiva Genomics Co.,Ltd. to Report Q1, 2025 Results on May 14, 2025 Sofiva Genomics Co.,Ltd. announced that they will report Q1, 2025 results on May 14, 2025 Valuation Update With 7 Day Price Move • Apr 08
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to NT$32.65, the stock trades at a trailing P/E ratio of 38.3x. Average trailing P/E is 17x in the Healthcare industry in Taiwan. Total loss to shareholders of 25% over the past three years. Announcement • Mar 13
Sofiva Genomics Co.,Ltd., Annual General Meeting, Jun 04, 2025 Sofiva Genomics Co.,Ltd., Annual General Meeting, Jun 04, 2025. Location: 3 floor no,195, hsing chung rd., neihu district, taipei city Taiwan New Risk • Nov 19
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 4.5% Last year net profit margin: 7.2% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 18% per year over the past 5 years. Minor Risks Profit margins are more than 30% lower than last year (4.5% net profit margin). Market cap is less than US$100m (NT$868.1m market cap, or US$26.7m). Announcement • Nov 06
Sofiva Genomics Co.,Ltd. to Report Q3, 2024 Results on Nov 13, 2024 Sofiva Genomics Co.,Ltd. announced that they will report Q3, 2024 results on Nov 13, 2024 Reported Earnings • Aug 17
Second quarter 2024 earnings released: EPS: NT$0.45 (vs NT$0.20 in 2Q 2023) Second quarter 2024 results: EPS: NT$0.45 (up from NT$0.20 in 2Q 2023). Revenue: NT$122.6m (up 2.9% from 2Q 2023). Net income: NT$9.55m (up 124% from 2Q 2023). Profit margin: 7.8% (up from 3.6% in 2Q 2023). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings. Announcement • Aug 08
Sofiva Genomics Co.,Ltd. to Report Q2, 2024 Results on Aug 14, 2024 Sofiva Genomics Co.,Ltd. announced that they will report Q2, 2024 results on Aug 14, 2024 Valuation Update With 7 Day Price Move • Jul 25
Investor sentiment deteriorates as stock falls 21% After last week's 21% share price decline to NT$65.20, the stock trades at a trailing P/E ratio of 70.3x. Average trailing P/E is 22x in the Healthcare industry in Taiwan. Total returns to shareholders of 45% over the past three years. Valuation Update With 7 Day Price Move • Jun 27
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to NT$74.00, the stock trades at a trailing P/E ratio of 79.7x. Average trailing P/E is 25x in the Healthcare industry in Taiwan. Total returns to shareholders of 68% over the past three years. Upcoming Dividend • Jun 26
Upcoming dividend of NT$0.20 per share Eligible shareholders must have bought the stock before 03 July 2024. Payment date: 26 July 2024. Payout ratio is a comfortable 22% but the company is not cash flow positive. Trailing yield: 0.3%. Lower than top quartile of Taiwanese dividend payers (4.2%). Lower than average of industry peers (3.1%). Declared Dividend • Jun 06
Dividend reduced to NT$0.20 Dividend of NT$0.20 is 80% lower than last year. Ex-date: 3rd July 2024 Payment date: 26th July 2024 Dividend yield will be 0.3%, which is lower than the industry average of 3.1%. New Risk • Jun 04
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 8.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.8% average weekly change). Earnings have declined by 14% per year over the past 5 years. Minor Risks Profit margins are more than 30% lower than last year (4.2% net profit margin). Market cap is less than US$100m (NT$1.20b market cap, or US$37.0m). Valuation Update With 7 Day Price Move • May 31
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to NT$56.60, the stock trades at a trailing P/E ratio of 61x. Average trailing P/E is 23x in the Healthcare industry in Taiwan. Total returns to shareholders of 33% over the past three years. Reported Earnings • May 19
First quarter 2024 earnings released: EPS: NT$0.58 (vs NT$0.20 in 1Q 2023) First quarter 2024 results: EPS: NT$0.58 (up from NT$0.20 in 1Q 2023). Revenue: NT$121.0m (up 7.1% from 1Q 2023). Net income: NT$12.5m (up 198% from 1Q 2023). Profit margin: 10% (up from 3.7% in 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings. Announcement • May 09
Sofiva Genomics Co.,Ltd. to Report Q1, 2024 Results on May 15, 2024 Sofiva Genomics Co.,Ltd. announced that they will report Q1, 2024 results on May 15, 2024 New Risk • Apr 03
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 2.5% Last year net profit margin: 8.6% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 11% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (2.5% net profit margin). Market cap is less than US$100m (NT$880.1m market cap, or US$27.5m). Announcement • Mar 16
Sofiva Genomics Co.,Ltd., Annual General Meeting, May 29, 2024 Sofiva Genomics Co.,Ltd., Annual General Meeting, May 29, 2024. Reported Earnings • Nov 14
Third quarter 2023 earnings released: EPS: NT$0.27 (vs NT$0.12 in 3Q 2022) Third quarter 2023 results: EPS: NT$0.27 (up from NT$0.12 in 3Q 2022). Revenue: NT$119.9m (flat on 3Q 2022). Net income: NT$5.77m (up 127% from 3Q 2022). Profit margin: 4.8% (up from 2.1% in 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has fallen by 11% per year, which means it is performing significantly worse than earnings. Announcement • Nov 09
Sofiva Genomics Co.,Ltd. Announces Resignation of Su,Yining as CEO Sofiva Genomics Co.,Ltd. announced resignation of SU,YINING as CEO. Effective date: November 7, 2023. Reported Earnings • Aug 13
Second quarter 2023 earnings released: EPS: NT$0.20 (vs NT$0.28 in 2Q 2022) Second quarter 2023 results: EPS: NT$0.20 (down from NT$0.28 in 2Q 2022). Revenue: NT$119.1m (down 8.2% from 2Q 2022). Net income: NT$4.27m (down 28% from 2Q 2022). Profit margin: 3.6% (down from 4.6% in 2Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 11% per year, which means it is performing significantly worse than earnings. Valuation Update With 7 Day Price Move • Aug 03
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to NT$44.95, the stock trades at a trailing P/E ratio of 29.4x. Average trailing P/E is 23x in the Healthcare industry in Taiwan. Total loss to shareholders of 17% over the past three years. Upcoming Dividend • Jun 30
Upcoming dividend of NT$1.00 per share at 2.5% yield Eligible shareholders must have bought the stock before 07 July 2023. Payment date: 31 July 2023. Payout ratio is a comfortable 65% but the company is not cash flow positive. Trailing yield: 2.5%. Lower than top quartile of Taiwanese dividend payers (5.5%). In line with average of industry peers (2.5%). Announcement • Jun 15
Sofiva Genomics Co.,Ltd. Declares Cash Dividend, Payable on July 31, 2023 The board of directors of Sofiva Genomics Co.,Ltd. declared cash dividend to shareholders of TWD 1 per share. Total amount of cash dividends to shareholders is TWD 21,362,400. Ex-rights (Ex-dividend) date is July 07, 2023; Ex-rights (Ex-dividend) record date is July 15, 2023 and Payment date of cash dividend distribution July 31, 2023. Valuation Update With 7 Day Price Move • May 09
Investor sentiment improves as stock rises 23% After last week's 23% share price gain to NT$46.90, the stock trades at a trailing P/E ratio of 23.4x. Average trailing P/E is 22x in the Healthcare industry in Taiwan. Total loss to shareholders of 14% over the past three years. Reported Earnings • Apr 06
Full year 2022 earnings released: EPS: NT$2.00 (vs NT$2.68 in FY 2021) Full year 2022 results: EPS: NT$2.00 (down from NT$2.68 in FY 2021). Revenue: NT$495.8m (down 2.5% from FY 2021). Net income: NT$42.8m (down 25% from FY 2021). Profit margin: 8.6% (down from 11% in FY 2021). Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has fallen by 13% per year, which means it is performing significantly worse than earnings. Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Aug 05
Second quarter 2022 earnings: EPS misses analyst expectations Second quarter 2022 results: EPS: NT$0.28 (down from NT$0.93 in 2Q 2021). Revenue: NT$129.6m (down 2.7% from 2Q 2021). Net income: NT$5.92m (down 70% from 2Q 2021). Profit margin: 4.6% (down from 15% in 2Q 2021). The decrease in margin was primarily driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 61%. Over the next year, revenue is forecast to grow 5.1%, compared to a 14% growth forecast for the industry in Taiwan. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 21% per year, which means it is performing significantly worse than earnings. Upcoming Dividend • Jun 29
Upcoming dividend of NT$2.00 per share Eligible shareholders must have bought the stock before 06 July 2022. Payment date: 28 July 2022. Payout ratio is a comfortable 68% and this is well supported by cash flows. Trailing yield: 4.4%. Lower than top quartile of Taiwanese dividend payers (6.3%). Higher than average of industry peers (3.3%). Announcement • Jun 17
Sofiva Genomics Co.,Ltd. Announces Cash Dividend, Payable on July 28, 2022 Sofiva Genomics Co.,Ltd. announced cash dividend of TWD 42,724,800 or TWD 2 per share. Payment date of cash dividend distribution is July 28, 2022. Ex-rights (Ex-dividend) record date is July 12, 2022. Ex-rights (Ex-dividend) date is July 6, 2022. Reported Earnings • May 09
First quarter 2022 earnings: EPS in line with expectations, revenues disappoint First quarter 2022 results: EPS: NT$0.67 (up from NT$0.42 in 1Q 2021). Revenue: NT$125.7m (flat on 1Q 2021). Net income: NT$14.3m (up 61% from 1Q 2021). Profit margin: 11% (up from 7.1% in 1Q 2021). Revenue missed analyst estimates by 14%. Earnings per share (EPS) were mostly in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 22% per year, which means it is performing significantly worse than earnings. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Nov 15
Third quarter 2021 earnings released: EPS NT$0.68 (vs NT$0.28 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: NT$125.3m (up 1.8% from 3Q 2020). Net income: NT$14.4m (up 146% from 3Q 2020). Profit margin: 12% (up from 4.8% in 3Q 2020). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 18% per year, which means it is performing significantly worse than earnings. Reported Earnings • Aug 18
Second quarter 2021 earnings released: EPS NT$0.93 (vs NT$0.40 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: NT$133.2m (up 8.2% from 2Q 2020). Net income: NT$19.7m (up 134% from 2Q 2020). Profit margin: 15% (up from 6.8% in 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has fallen by 27% per year, which means it is performing significantly worse than earnings. Upcoming Dividend • Jul 05
Upcoming dividend of NT$1.40 per share Eligible shareholders must have bought the stock before 12 July 2021. Payment date: 06 August 2021. Trailing yield: 2.8%. Lower than top quartile of Taiwanese dividend payers (5.0%). In line with average of industry peers (3.1%). Reported Earnings • Jun 12
First quarter 2021 earnings released: EPS NT$0.42 (vs NT$0.49 in 1Q 2020) The company reported a soft first quarter result with weaker earnings and profit margins, although revenues improved. First quarter 2021 results: Revenue: NT$124.6m (up 4.6% from 1Q 2020). Net income: NT$8.91m (down 15% from 1Q 2020). Profit margin: 7.1% (down from 8.8% in 1Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 25% per year, which means it is performing significantly worse than earnings. Reported Earnings • May 17
First quarter 2021 earnings released: EPS NT$0.42 (vs NT$0.49 in 1Q 2020) The company reported a soft first quarter result with weaker earnings and profit margins, although revenues improved. First quarter 2021 results: Revenue: NT$124.6m (up 4.6% from 1Q 2020). Net income: NT$8.91m (down 15% from 1Q 2020). Profit margin: 7.1% (down from 8.8% in 1Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 29% per year, which means it is performing significantly worse than earnings. Valuation Update With 7 Day Price Move • Apr 15
Investor sentiment improved over the past week After last week's 19% share price gain to NT$58.00, the stock trades at a trailing P/E ratio of 35.6x. Average trailing P/E is 18x in the Healthcare industry in Taiwan. Total loss to shareholders of 45% over the past three years. Reported Earnings • Mar 30
Full year 2020 earnings released: EPS NT$1.63 (vs NT$2.96 in FY 2019) The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: NT$488.9m (down 4.0% from FY 2019). Net income: NT$34.6m (down 45% from FY 2019). Profit margin: 7.1% (down from 12% in FY 2019). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has fallen by 22% per year, which means it is performing significantly worse than earnings. Is New 90 Day High Low • Jan 27
New 90-day low: NT$50.60 The company is down 11% from its price of NT$56.70 on 29 October 2020. The Taiwanese market is up 23% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is down 4.0% over the same period. Is New 90 Day High Low • Dec 28
New 90-day low: NT$51.60 The company is down 11% from its price of NT$58.20 on 30 September 2020. The Taiwanese market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is down 1.0% over the same period. Is New 90 Day High Low • Dec 11
New 90-day low: NT$54.00 The company is down 7.0% from its price of NT$58.20 on 11 September 2020. The Taiwanese market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is down 2.0% over the same period. Reported Earnings • Nov 14
Third quarter 2020 earnings released: EPS NT$0.28 The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2020 results: Revenue: NT$123.1m (down 5.6% from 3Q 2019). Net income: NT$5.85m (down 67% from 3Q 2019). Profit margin: 4.8% (down from 13% in 3Q 2019). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 13% per year, which means it is performing significantly worse than earnings. Is New 90 Day High Low • Nov 02
New 90-day low: NT$55.00 The company is down 8.0% from its price of NT$60.00 on 04 August 2020. The Taiwanese market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is up 6.0% over the same period.